IL-6 peaks are temporary in CAR-T patients, particularly if therapy is in place, but IL-6 levels persist in COVID-19 patients for an extended period of time [102].IL-6 clinical cut-off values that are recommended in this context are beginning to appear, despite the small sample size [38,78]. This evidence concerns the gene IL6 and COVID-19.